BioMarin price target raised to $72 from $65 at Leerink Leerink raised its price target for BioMarin after increasing its probability of success for BMN-701 to 60% from 30% following yesterday's data. The firm reiterates an Outperform rating on the stock.
BioMarin upgraded to Buy from Neutral at Goldman Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.